1st Quarter - Report

VIZIENT, INC. for VIZIENT INC

Firm
Client
Income
—
Expenses
$45,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Hospital Group Purchasing - Conducted outreach efforts to promote the value offered to hospitals by group purchasing organizations. 340B Drug Discount Program - Advocated for the Health Resources and Services Administration to provide additional time to hospitals to comply with revised guidance on the GPO exclusion utilized by the program.House and Senate Budget Resolutions - Tracked negotiations over House and Senate Budget resolutions. Opposed proposals that would reduce reimbursement for hospitals. Shortage of Prescription Drugs - monitored expanding regulatory efforts from the Food and Drug Administration related to compounding pharmacies. Supported efforts to ensure quality compounding and manufacturing processes, while ensuring integrity in the prescription drug supply-chain.

LobbyistCovered position, as disclosed
EDWARD GOODMAN —
CIDETTE PERRIN —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Not-for-profit hospital tax exemption - Advocated for the release of formal guidance related to Section 501(r) of the Affordable Care Act related to community health needs assessments for tax exempt hospitals. Supported maintaining current tax-exempt financing provisions in potential tax reform efforts being considered by Congress.

LobbyistCovered position, as disclosed
EDWARD GOODMAN —
CIDETTE PERRIN —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Internal Revenue Service (IRS); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Sustainable Growth Rate Formula (H.R.574, Senate Finance, House Energy and Commerce and House Ways and Means Committee drafts) - monitored ongoing discussions to replace the sustainable growth rate formula for Medicare reimbursement for physicians. Advocated against further cuts to hospital payments in order to offset replacement costs. Budget Control Act - Urged Congress to pass legislation to avoid or delay sequestration Medicare reimbursement cuts for hospitals.

LobbyistCovered position, as disclosed
EDWARD GOODMAN —
CIDETTE PERRIN —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 574 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.